A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Shin-young Oh
- Phone Number: +82+2-708-8000
- Email: syoh@boryung.co.kr
Study Locations
-
-
-
Daegu, South Korea
- Recruiting
- Kyungbook National university hospital
-
Contact:
- Seung-hee Won
-
Guri-si, South Korea
- Not yet recruiting
- Hanyang University Guri Hospital
-
Contact:
- JoonHo Choi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Of patients with schizophrenia in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria, who are judged that administration of low dose is more appropriate than initial recommended dose or standard titration dose of olanzapine to consider medical conditions by investigator
- Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)
Exclusion Criteria:
- Patients diagnosed schizophrenia spectrum and other psychotic disorder(e.g. schizoaffective disorder, etc.), bipolar disorder, depressive disorder, etc., in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria at screening visit(Visit 1)
- Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Gradual titration group
|
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Other Names:
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Other Names:
|
|
Active Comparator: Conventional titration group
|
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Other Names:
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Other Names:
Subjects take the investigational products once a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The mean change of PANSS(Positive and Negative Syndrome Scale) total score
Time Frame: 1, 2, 3, 5, 9 weeks from baseline(Visit 2)
|
1, 2, 3, 5, 9 weeks from baseline(Visit 2)
|
|
Incidence of treatment-emergent adverse events
Time Frame: From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)
|
From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BR-OLZ-CT-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.